Hyperlipen (Ciprofibrate)

Ciprofibrate activates the nuclear receptor PPARα, which increases the expression of enzymes responsible for fatty‑acid oxidation and reduces the synthesis of triglycerides, thereby enhancing clearance of triglyceride‑rich lipoproteins from the bloodstream.

The dosage of Hyperlipen is individualized by the prescribing clinician based on the patient’s lipid levels, renal and hepatic function, and overall risk profile. The prescriber determines the appropriate strength and frequency.

Safety data for ciprofibrate during pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant, and only under medical supervision.

To request Hyperlipen, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with statins, which primarily lower LDL‑cholesterol, ciprofibrate is more effective at reducing triglycerides and modestly raising HDL‑cholesterol. Unlike other fibrates such as gemfibrozil, ciprofibrate may have a lower incidence of certain drug‑drug interactions but still requires caution when combined with statins.

Hyperlipen should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Hyperlipen is taken orally, usually once daily with a meal to enhance absorption and reduce gastrointestinal upset. Patients should swallow the tablet whole with water and follow the prescriber’s instructions regarding timing and food.

The most serious adverse events include myopathy or rhabdomyolysis, especially when used with statins, severe liver injury, gallstone formation, and rare cases of acute pancreatitis. Patients should report unexplained muscle pain, dark urine, jaundice, or severe abdominal pain promptly.

Hyperlipen is contraindicated in patients with active liver disease, severe renal impairment, known gallbladder disease, or a documented hypersensitivity to ciprofibrate or any component of the formulation.